On Friday, the pharmaceutical company Biogen announced the Food and Drug Administration accepted its application to conduct a priority review of their experimental Alzheimer’s drug for approval. The speedier-than-usual process sets the stage for the treatment, called aducanumab, to be the first new approved drug for…
from Gizmodo https://ift.tt/3fJCbaM
EmoticonEmoticon